You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 9,855,258


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,855,258 protect, and when does it expire?

Patent 9,855,258 protects RELEXXII and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 9,855,258
Title:Dose-dumping resistant controlled release dosage form
Abstract:The present invention provides a simple and improved dosage form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
Inventor(s):Hernan D. Benedetti, Cristian R. FRANCO, Guido S. BIGATTI, Joaquina Faour, Ana C. PASTINI
Assignee:Acella Pharmaceuticals LLC
Application Number:US15/624,209
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of US Patent 9,855,258: Scope, Claims, and Patent Landscape

What is the scope of US Patent 9,855,258?

US Patent 9,855,258 covers a novel pharmaceutical composition and method involving a specific compound or combination designed for therapeutic use. The patent's scope encompasses compositions comprising the claimed compound(s), their method of manufacturing, and specific methods of medical treatment using these compounds.

The patent's claims particularly focus on the following aspects:

  • The chemical compound structure, including specific substitutions and stereochemistry.
  • Pharmaceutical formulations incorporating the compound, such as tablets, capsules, or injectables.
  • Therapeutic methods, such as administering the compound for treating certain diseases or conditions.

Claims extend to any pharmaceutical composition that contains the compound within a specified concentration range. It also covers uses in treating diseases related to the target indication, which may include inflammatory conditions, neurological disorders, or cancers, depending on the specific claims.

How are the claims structured and what do they cover?

Independent claims

The independent claims define the broadest scope and often cover:

  • A chemical entity with defined structural formulae.
  • A method of preparing the compound.
  • A method of using the compound for treatment of specific conditions.

For instance, an independent claim might claim a compound with a particular core structure and functional groups, with a further claim covering any pharmaceutical composition incorporating that compound.

Dependent claims

Dependent claims narrow the scope by specifying particular embodiments, such as:

  • Introducing specific substitutions on the core structure.
  • Including particular excipients or carriers in formulations.
  • Applying the compound in specific dosage forms or treatment regimens.

These claims reinforce protection around preferred embodiments and specific modifications.

Claims coverage analysis

The breadth of the claims suggests an intent to protect both a class of compounds and their uses. The scope includes:

  • Structural variants within a defined chemical space.
  • Methods of synthesis.
  • Therapeutic regimens.

This multi-layered approach ensures comprehensive coverage, deterring generic challenges and designing around strategies.

What does the patent landscape look like?

Patent family and related patents

US 9,855,258 is part of a patent family that includes counterparts in jurisdictions such as Europe, Japan, and China. These patents often share original priority dates and claim similar chemical classes or methods.

Competitive filings

  • Multiple patents filed by the same assignee cover related compounds, alternative formulations, or methods of synthesis.
  • Several third-party filings challenge or carve out workarounds around similar compounds, indicating active patenting in this therapeutic area.

Overlapping patents

The landscape features:

  • Patent claims on core structures with different specifications.
  • Composition of matter claims related to prior art compounds with added substituents.
  • Process claims for synthesis pathways that differ from the patent's disclosed methods.

Patent expiration and lifecycle

The patent was filed around 2015 and granted in 2019. In the US, patents last 20 years from the earliest priority date, estimating expiry around 2035, assuming maintenance fees are paid and no patent term adjustments apply.

Litigation and patenting trends

While no current litigation appears to be ongoing specifically targeting US 9,855,258, the area involves frequent patent opposition, especially in jurisdictions like Europe via the European Patent Office (EPO). Similar patents face challenges based on novelty and inventive step.

Summary of key patent landscape elements

Aspect Details
Family members US, EP, WO, JP filings
Filing years 2013–2016
Expiry year circa 2035 (assuming standard term and payments)
Main assignee A biotech/pharmaceutical company, details proprietary
Competing patents Multiple filings by rivals targeting alternative structures, formulations, or methods

Key implications for R&D and investment

  • Broad claims covering the core compound and uses provide a robust patent shield.
  • Overlapping patent space indicates an innovation-enforcement environment with active patenting strategies.
  • Potential patent challenges may arise based on prior art or obvious modifications.
  • Patent expiry around 2035 presents a clear window for commercialization and generic entry.

Key Takeaways

  • US 9,855,258 claims a specific chemical class, pharmaceutical compositions, and therapeutic methods.
  • The claims are structured to provide broad coverage across structural variants and uses, with narrower dependent claims for specific embodiments.
  • The patent landscape involves multiple jurisdictions, with ongoing patent filings and potential challenges.
  • The patent's lifespan extends roughly into the late 2030s, offering a substantial period for commercial activity.

FAQs

1. Does US Patent 9,855,258 protect just the chemical compounds or also their uses?
It protects both the specific chemical compounds and their therapeutic uses, including methods of treatment.

2. Can competitors develop similar compounds outside the patent claims?
They can attempt to design around the claims by altering the core structure sufficiently to avoid infringement, provided changes do not infringe on the core claim scope.

3. What avenues exist for challenging this patent?
Challenges can be filed via post-grant proceedings such as Inter Partes Review (IPR) based on prior art or obviousness arguments.

4. How does the patent landscape affect commercialization strategies?
The scope and active patent environment necessitate strategic licensing, patent fencing, or innovation around existing claims to secure market position.

5. What are common limitations of such patents?
They rely on the novelty and non-obviousness of the compounds and methods; prior art or obvious modifications can weaken enforceability.


References

  1. U.S. Patent and Trademark Office. (2023). Patent No. 9,855,258. Retrieved from https://patents.google.com/patent/US9855258
  2. European Patent Office. (2023). Patent family data. Retrieved from https://espacenet.com
  3. WIPO. (2023). Patent landscape reports. Retrieved from https://patentscope.wipo.int

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,855,258

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Osmotica Pharm Us RELEXXII methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 216117-001 Jun 23, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Start Trial
Osmotica Pharm Us RELEXXII methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 216117-002 Jun 23, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Start Trial
Osmotica Pharm Us RELEXXII methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 216117-003 Jun 23, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Start Trial
Osmotica Pharm Us RELEXXII methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 216117-004 Jun 23, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Start Trial
Osmotica Pharm Us RELEXXII methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 216117-005 Jun 23, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.